Filtered By:
Condition: Arthritis
Infectious Disease: COVID-19
This page shows you your search results in order of date.
Order by Relevance | Date
Total 24 results found since Jan 2013.
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases
Vasa. 2022 Oct 6. doi: 10.1024/0301-1526/a001031. Online ahead of print.ABSTRACT Vascular adhesion protein-1 (VAP-1) also known as amino oxidase copper containing 3 (AOC3) is a pro-inflammatory and versatile molecule with adhesive and enzymatic properties. VAP-1 is a primary amine oxidase belonging to the semicarbazide-sensitive amine oxidase (SSAO) family, which catalyzes the oxidation of primary amines leading to the production of ammonium, formaldehyde, methylglyoxal, and hydrogen peroxide. VAP-1 is mainly expressed by endothelial cells, smooth muscle cells, adipocytes and pericytes. It is involved in a repertoire of bi...
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - October 6, 2022 Category: Surgery Authors: Marianna Danielli Roisin Clare Thomas Lauren Marie Quinn Bee Kang Tan Source Type: research
